

# Valdis Pirags

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4143774/valdis-pirags-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91  
papers

8,760  
citations

30  
h-index

93  
g-index

96  
ext. papers

10,406  
ext. citations

8.1  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
91	Achievement of treatment targets predicts progression of vascular complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 108072	3.2	1
90	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , <b>2021</b> , 42, 2565-2573	9.5	7
89	Report on Bariatric Surgery in Latvia. <i>Obesity Surgery</i> , <b>2021</b> , 31, 2311-2313	3.7	
88	Antibacterial and Anti-Inflammatory Potential of Polyherbal Formulation Used in Chronic Wound Healing. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 9991454	2.3	2
87	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 484-490	18.1	2
86	Hypercalcemia and CYP24A1 Gene Mutation Diagnosed in the 2nd Trimester of a Twin Pregnancy: A Case Report. <i>American Journal of Case Reports</i> , <b>2021</b> , 22, e931116	1.3	0
85	Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 313	5.7	2
84	Standardized Map of Iodine Status in Europe. <i>Thyroid</i> , <b>2020</b> , 30, 1346-1354	6.2	21
83	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. <i>Lancet Neurology</i> , <b>2020</b> , 19, 582-590	24.1	48
82	Angiotensin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2020</b> , 128, 654-662	2.3	5
81	Case report: recurrent pituitary adenoma has increased load of somatic variants. <i>BMC Endocrine Disorders</i> , <b>2020</b> , 20, 17	3.3	2
80	Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241338	3.7	8
79	Nitric oxide metabolism is impaired by type 1 diabetes and diabetic nephropathy. <i>Biomedical Reports</i> , <b>2020</b> , 12, 251-258	1.8	5
78	Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diabetes - InterDiane Consortium. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 170, 108495	7.4	1
77	Impact of interval walking training managed through smart mobile devices on albuminuria and leptin/adiponectin ratio in patients with type 2 diabetes. <i>Physiological Reports</i> , <b>2020</b> , 8, e14506	2.6	2
76	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 199	8.7	3
75	Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237400	3.7	11

74	Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 593760	5.3	2
73	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2019</b> , 394, 121-130	4.0	917
72	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2019</b> , 394, 131-138	4.0	228
71	Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 615	5.7	2
70	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 2000-2016	12.7	66
69	Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224835	3.7	8
68	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. <i>European Journal of Endocrinology</i> , <b>2019</b> , 181, 461-472	6.5	23
67	Consumption of Thyroid Medications as an Indicator of Increase of Thyroid Morbidity in Latvia from 2011 to 2014. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2019</b> , 73, 407-410	0.3	0
66	Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 270-276	4	50
65	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 42-49	6.7	121
64	Pepsinogen test for the evaluation of precancerous changes in gastric mucosa: a population-based study. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2018</b> , 27, 11-17	1.4	8
63	Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals. <i>Clinical Epigenetics</i> , <b>2018</b> , 10, 156	7.7	13
62	Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204317	3.7	60
61	Iodine Deficiency in Latvia: Current Status and Need for National Recommendations. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2017</b> , 71, 401-407	0.3	0
60	Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 763-772	6.1	60
59	Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. <i>European Journal of Endocrinology</i> , <b>2016</b> , 175, 531-540	6.5	16
58	Ensuring Effective Prevention of Iodine Deficiency Disorders. <i>Thyroid</i> , <b>2016</b> , 26, 189-96	6.2	26
57	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). <i>Diabetes Care</i> , <b>2016</b> , 39, 709-16	14.6	48

56	Functional Characteristics of Multipotent Mesenchymal Stromal Cells from Pituitary Adenomas. <i>Stem Cells International</i> , <b>2016</b> , 2016, 7103720	5	8
55	Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas. <i>European Journal of Endocrinology</i> , <b>2016</b> , 175, 145-53	6.5	10
54	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , <b>2016</b> , 48, 1055-1059	36.3	108
53	Trefoil factor 3 is required for differentiation of thyroid follicular cells and acts as a context-dependent tumor suppressor. <i>Neoplasia</i> , <b>2015</b> , 62, 914-24	3.3	8
52	Iodine deficiency during pregnancy: a national cross-sectional survey in Latvia. <i>Public Health Nutrition</i> , <b>2015</b> , 18, 2990-7	3.3	16
51	Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 190-9	5.3	8
50	The role of common and rare MC4R variants and FTO polymorphisms in extreme form of obesity. <i>Molecular Biology Reports</i> , <b>2014</b> , 41, 1491-500	2.8	12
49	Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. <i>Cancer Biomarkers</i> , <b>2014</b> , 14, 361-9	3.8	8
48	A cross-sectional survey of urinary iodine status in Latvia. <i>Medicina (Lithuania)</i> , <b>2014</b> , 50, 124-9	3.1	11
47	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , <b>2014</b> , 37, 1360-6	14.6	67
46	Selenium status in patients with autoimmune and non-autoimmune thyroid diseases from four European countries. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2014</b> , 9, 685-692	4.1	6
45	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. <i>Diabetes Care</i> , <b>2014</b> , 37, 1924-30	14.6	40
44	Polymorphisms in FTO and near TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes. <i>Gene</i> , <b>2013</b> , 527, 462-8	3.8	18
43	Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. <i>Lipids in Health and Disease</i> , <b>2013</b> , 12, 103	4.4	3
42	The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 513-22	6.7	4
41	Identification of glyoxalase 1 polymorphisms associated with enzyme activity. <i>Gene</i> , <b>2013</b> , 515, 140-3	3.8	29
40	Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients. <i>Journal of Diabetes and Its Complications</i> , <b>2013</b> , 27, 262-7	3.2	31
39	A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. <i>Diabetes and Vascular Disease Research</i> , <b>2013</b> , 10, 277-86	3.3	16

38	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. <i>Diabetes Care</i> , <b>2013</b> , 36, 565-8	14.6	48
37	Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 852-8	6.7	54
36	Single nucleotide polymorphisms of the purinergic 1 receptor are not associated with myocardial infarction in a Latvian population. <i>Molecular Biology Reports</i> , <b>2012</b> , 39, 1917-25	2.8	13
35	Seasonal iodine deficiency in Latvian school children. <i>Thyroid</i> , <b>2012</b> , 22, 1088-9	6.2	10
34	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 309-18	59.2	659
33	Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings. <i>International Journal of Clinical Practice</i> , <b>2012</b> , 66, 1033-41	2.9	6
32	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. <i>Nature Medicine</i> , <b>2012</b> , 18, 926-33	50.5	339
31	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 319-28	59.2	1138
30	Stronger association of common variants in TCF7L2 gene with nonobese type 2 diabetes in the Latvian population. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2012</b> , 120, 466-8	2.3	5
29	Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 1410-7	2.2	32
28	Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 659-66	1.9	85
27	Acute and multiple-dose studies to determine the safety, tolerability, and pharmacokinetic profile of advantame in healthy volunteers. <i>Food and Chemical Toxicology</i> , <b>2011</b> , 49 Suppl 1, S77-83	4.7	6
26	Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules. <i>Thyroid Research</i> , <b>2011</b> , 4, 11	2.4	5
25	Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. <i>European Journal of Endocrinology</i> , <b>2011</b> , 165, 517-25	6.5	18
24	A nonsynonymous variant I248L of the adenosine A3 receptor is associated with coronary heart disease in a Latvian population. <i>DNA and Cell Biology</i> , <b>2011</b> , 30, 907-11	3.6	10
23	Incidence of diabetes following ramipril or rosiglitazone withdrawal. <i>Diabetes Care</i> , <b>2011</b> , 34, 1265-9	14.6	28
22	Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. <i>Circulation</i> , <b>2010</b> , 121, 1176-87	16.7	71
21	Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 2163-71	5.6	50

20	Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. <i>Diabetologia</i> , <b>2010</b> , 53, 1258-69	10.3	72
19	Association between a rare SNP in the second intron of human Agouti related protein gene and increased BMI. <i>BMC Medical Genetics</i> , <b>2009</b> , 10, 63	2.1	15
18	Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. <i>European Journal of Internal Medicine</i> , <b>2009</b> , 20, 712-7	3.9	16
17	Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). <i>Atherosclerosis</i> , <b>2009</b> , 202, 272-81	3.1	58
16	Relation of Endothelial Dysfunction and Adipokines Levels to Insulin Resistance in Metabolic Syndrome Patients. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2009</b> , 63, 222-227	0.3	
15	Glucose Metabolism Disorders and Risk Factors of Type 2 Diabetes in 45-74-Years-old Population in Rīga, Latvia. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2009</b> , 63, 141-146	0.3	
14	Analysis of Polymorphisms at the Adiponectin Gene Locus in Association with Type 2 Diabetes, Body Mass Index and Cardiovascular Traits in Latvian Population. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2009</b> , 63, 174-179	0.3	2
13	Bioinformatic Analysis of Evolutional Conservatism and Functional Significance of Microsatellite Alleles of Human 14Q13.2 Region Associated with Type 2 Diabetes Mellitus. <i>Proceedings of the Latvian Academy of Sciences</i> , <b>2008</b> , 62, 91-102	0.3	1
12	Association of microsatellite polymorphisms of the human 14q13.2 region with type 2 diabetes mellitus in Latvian and Finnish populations. <i>Annals of Human Genetics</i> , <b>2007</b> , 71, 772-6	2.2	18
11	SNPs of the PSMA6 gene: Investigation of possible association with myocardial infarction and type 2 diabetes mellitus. <i>Russian Journal of Genetics</i> , <b>2007</b> , 43, 444-450	0.6	0
10	Interleukin-6 gene promoter -174G/C polymorphism and insulin resistance: a pilot study. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2007</b> , 45, 1145-8	5.9	1
9	Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). <i>Stroke</i> , <b>2007</b> , 38, 865-73	6.7	374
8	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet, The</i> , <b>2005</b> , 366, 1279-89	40	3186
7	The Diabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2005</b> , 6, 25-32	3	54
6	Microsatellite genotyping of chromosome 14q13.2-14q13 in the vicinity of proteasomal gene PSMA6 and association with GravesDisease in the Latvian population. <i>Immunogenetics</i> , <b>2004</b> , 56, 238-43 <sup>3,2</sup>		14
5	Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. <i>Medical Principles and Practice</i> , <b>2003</b> , 12, 10-6	2.1	12
4	The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2002</b> , 3, 255-61	3	44
3	Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. <i>Diabetologia</i> , <b>2001</b> , 44, 188-95	10.3	106

- 2 Two HLA DRB 1 alleles confer independent genetic susceptibility to Graves disease: relevance of cross-population studies. *American Journal of Medical Genetics Part A*, **2001**, 102, 188-91 3<sup>1</sup>
- 1 Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen 2